|Bid||40.85 x 400|
|Ask||40.89 x 200|
|Day's Range||40.79 - 41.48|
|52 Week Range||37.20 - 45.58|
|PE Ratio (TTM)||46.00|
|Dividend & Yield||1.95 (4.62%)|
|1y Target Est||N/A|
GlaxoSmithKline's new chief executive announced plans on Wednesday to narrow the focus of the group's drug research by ditching more than 30 drug projects to improve returns in its core pharmaceuticals ...
GlaxoSmithKline is swimming against the tide by getting out of treatments for rare diseases at a time when rivals like Sanofi and Shire see the field as a rich seam for profits. Successful medicines for rare conditions are potentially very lucrative, since prices frequently run into hundreds of thousands of dollars, but patient numbers can be extremely low. New GSK Chief Executive Emma Walmsley announced the strategic review and potential divestment of rare diseases on Wednesday as part of a wide-ranging drive to streamline pharmaceutical operations.